3'-Selenobisalanine" No Further a Mystery
All enrolled people who obtained at least one particular dose of zosuquidar or placebo throughout induction ended up monitored with the occurrence of adverse activities (439 clients, 219 on zosuquidar and 210 on placebo). The commonest adverse events had been connected with the period of prolonged and important myelosuppression as is predicted with